Galapagos establishes strategic collaboration with BridGene Biosciences to expand small molecule drug discovery in oncology

Galapagos to pay up to $27 million in upfront and preclinical milestone payments to BridGene

08-Jan-2024 - Galapagos NV announced that it has entered into a strategic collaboration and licensing agreement with BridGene Biosciences, Inc. (“Bridgene”), a biotechnology company that uses proprietary chemoproteomics technology to discover novel small molecule drug candidates. Through this collaboration, ...

BioFocus has signed an integrated drug discovery collaboration with Boehringer Ingelheim

21-Nov-2013 - Galapagos announced that its BioFocus subsidiary signed a new collaboration agreement with Boehringer Ingelheim. Under the terms of the agreement, BioFocus will apply its extensive drug discovery services to an undisclosed target within Boehringer Ingelheim’s drug discovery portfolio. David ...

Galapagos subsidiary BioFocus and Ono sign a drug discovery agreement in the Field of CNS Disorders

04-Sep-2012 - Galapagos NV announced that its service division BioFocus and Ono Pharmaceutical Co., Ltd. have signed a new collaboration agreement, focused on discovering novel drugs in the field of CNS disorders. Under the new agreement, BioFocus will use its drug discovery platform to deliver leads and ...

Almirall and BioFocus enter research alliance

Three-year integrated drug discovery alliance is for identifying drug development candidates for treating respiratory disease

26-Jan-2012 - Almirall, S.A. announced that it has formed a research alliance with BioFocus, an affiliate from Galapagos NV.The three-year alliance is aimed at delivering drug development candidates directed to a key respiratory target of interest to Almirall. Under the terms of the collaboration, BioFocus ...

Galapagos and Genentech extend drug discovery collaboration

19-Aug-2011 - Galapagos NV announced that its service division Argenta has extended its integrated contract drug discovery agreement with Genentech, a member of the Roche Group. Total potential value of the contract extension is up to £21.5million (€23.4million). This is the third such extension since the ...

Galapagos receives €2.7 million grant for antiviral drug discovery

08-Feb-2011 - Galapagos NV announced that it has been awarded a €2.7 million grant from the Flemish agency for Innovation by Science and Technology (IWT) to progress its proprietary antiviral drug discovery research programs.The two-year IWT-funded project focuses on progressing novel mode-of-action small ...

Argenta expands collaboration with Genentech to include BioFocus

14-Sep-2010 - Argenta, a service division of Galapagos NV, announced it has signed a contract extension with Genentech, Inc., a member of the Roche Group. The extended agreement expands the portfolio of projects which are in collaboration with Genentech and allows Genentech to place projects directly into ...

KINAXO enters into US and Japanese partnerships to introduce its Cellular Target Profiling Service

17-Oct-2008 - KINAXO Biotechnologies GmbH announced that it has entered into strategic sales and marketing partnerships with BioCatalyst International and BioFocus DPI to support the introduction of KINAXO’s proprietary Cellular Target Profiling™ Service within the US and Japanese market. According to the ...

Galapagos acquires structure-based drug discovery from Sareum

28-Aug-2008 - Galapagos NV and Sareum Holdings plc announced that Galapagos has acquired Sareum's assets in drug discovery services, for a total cash consideration of €695,000 (£553,000). According to the company, these assets will position Galapagos' service division BioFocus DPI strongly in the growing ...

Galapagos announces PPAR-delta commercial license agreement with Hillcrest Therapeutics

02-Feb-2007 - Galapagos NV announced that it has signed an exclusive commercial license agreement with US-based Hillcrest Therapeutics, Inc., in which Hillcrest was granted worldwide rights to develop and commercialize the PPAR-delta technology in all fields. PPAR-delta, a drug discovery program addressing ...